Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Src activation regulates anoikis in human colon tumor cell lines

Oncogene volume 21, pages 7797–7807 (2002)Cite this article

Abstract

Src is a non-receptor protein tyrosine kinase, the expression and activity of which is increased in >80% of human colon cancers with respect to normal colonic epithelium. Previous studies from this and other laboratories have demonstrated that Src activity contributes to tumorigenicity of established colon adenocarcinoma cell lines. Src participates in the regulation of many signal transduction pathways, among which are those leading to cellular survival. In this study, we addressed the potential role of Src activation to a specific aspect of tumor cell survival, resistance to detachment-induced apoptosis (anoikis). Using five colon tumor cell lines with different biologic properties and genetic alterations, we demonstrate that expression and activity of Src corresponds with resistance to anoikis. Enforced expression of activated Src in subclones of SW480 cells (of low intrinsic Src expression and activity) increases resistance to anoikis; whereas decreased Src expression in HT29 cells (of high Src expression and activity) by transfection with anti-sense Src expression vectors increases susceptibility to anoikis. In contrast, increasing or decreasing Src expression had no effect on susceptibility to staurosporine-induced apoptosis in attached cells. PD173955, a Src family-specific tyrosine kinase inhibitor, increases the susceptibility of HT29 cells to anoikis in a dose- and time-dependent manner. Increasing Src expression and activity led to increased phosphorylation of Akt, a mediator of cellular survival pathways, whereas decreasing Src activity led to decreased Akt phosphorylation. In colon tumor cells with high Src activity, the PI3 kinase inhibitor LY 294002 sensitized cells to anoikis. These results suggest that Src activation may contribute to colon tumor progression and metastasis in part by activating Akt-mediated survival pathways that decrease sensitivity of detached cells to anoikis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 8
Figure 7
Figure 9

Similar content being viewed by others

References

  • Allgayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE . 2002 Cancer 94: 344–351

  • Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD . 1999 J. Biol. Chem. 274: 18428–18437

  • Barvian MR, Klutchko S, Hamby JM, Kraker AJ, Moore C, Hart BJ, Lu GH, Panek RL, Fry DW, Doherty AM, Showalter HDH . 1998 Proc. Am. Assoc. Cancer Res. 39: 176

  • Bolen JB, Veillett A, Schwartz AM, DeSeau V, Rosen N . 1987 Proc. Natl. Acad. Sci. 84: 2251–2255

  • Burridge K, Turner CE, Romer LH . 1992 J. Cell Biol. 119: 893–903

  • Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W . 1989 J. Clin. Invest. 83: 2025–2033

  • Cartwright CA, Mamajiwalla S, Skolnick SA, Eckhart W, Burgess DR . 1993 Oncogene 8: 1033–1039

  • Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y . 2001 J. Biol. Chem. 276: 31858–31862

  • Coll ML, Rosen K, Ladeda V, Filmus J . 2002 Oncogene 21: 2908–2913

  • Daigo Y, Furukawa Y, Kawasoe T, Ishiguro H, Fujita M, Sugai S, Nakamori S, Liefers GJ, Tollenaar RA, van de Velde CJ, Nakamura Y . 1999 Cancer Res. 59: 4222–4224

  • Defilippi P, Bozzo C, Volpe G, Romano G, Venturino M, Silengo L, Tarone G . 1994 Cell Adhesion Commun. 2: 75–86

  • Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA . 1999 Mol. Cell 4: 915–924

  • Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD, Gallick GE . 1998 J. Biol. Chem. 273: 1052–1057

  • Fincham VJ, Brunton VC, Frame MC . 2000 Mol. Cell Biol. 20: 6518–6536

  • Fleming RYD, Ellis LM, Parikh NU, Liu W, Staley CA, Gallick GE . 1997 Surgery 122: 501–507

  • Foss FM, Veillette A, Sartor O, Rosen N, Bolen JB . 1989 Onc. Res. 5: 13–23

  • Frisch SM, Francis H . 1994 J. Cell Biol. 124: 619–626

  • Frisch SM, Screaton RA . 2001 Curr. Opin. Cell Biol. 13: 555–562

  • Frisch S, Vuori K, Ruoslahti E, Chan-Hui PY . 1996 J. Cell Biol. 134: 793–799

  • Garcia R, Parikh NU, Saya H, Gallick GE . 1991 Oncogene 6: 1983–1989

  • Grossmann J, Walther K, Artinger M, Kiesslong S, Schlolmerich J . 2001 J. Cell Growth Diff. 12: 147–155

  • Gavrieli Y, Sherman Y, Ben-Sasson SA . 1992 J. Cell Biol. 119: 493–501

  • Gervais FG, Thornberg NA, Ruffolo SC, Nicholson DW, Roy S . 1998 J. Biol. Chem. 273: 17102–17108

  • Guan JL, Trevithick JE, Hynes RO . 1991 Cell Regul. 2: 951–964

  • Hall PA, Coates PJ, Ansari B, Hopwood D . 1994 J. Cell Sci. 107: 3569–3577

  • Howe A, Aplin AE, Alahari SK, Juliano RL . 1998 Curr. Opin. Cell Biol. 10: 220–231

  • Huang M, Lipfert L, Cunningham M, Brugge JS, Ginsberg MH, Shattil SJ . 1993 J. Cell Biol. 122: 473–483

  • Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ . 1999 Nature Genetics 21: 187–190

  • Irby R, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ . 1997 Cell Growth Differ. 8: 1287–1295

  • Irby RB, Yeatman TJ . 2000 Oncogene 19: 5636–5642

  • Jessup JM, Gallick GE . 1992 Curr. Prob. Cancer 16: 263–328

  • Jost M, Huggett TM, Kari C, Rodeck U . 2001 Mol. Biol. Cell. 12: 1519–1527

  • Karni R, Jove R, Levitzki A . 1999 Oncogene 18: 4654–4662

  • Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J . 1997 EMBO J. 16: 2783–2793

  • Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P . 1999 EMBO J. 18: 2459–2471

  • Kmiecik TE, Shalloway D . 1987 Cell 49: 65–73

  • Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL . 1992 J. Biol. Chem. 267: 23439–23442

  • Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS . 1992 J. Cell Biol. 119: 905–912

  • Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N . 1999 Cancer Res. 59: 6145–6152

  • Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukatme VP . 1995 Nature 375: 843–845

  • Paul R, Zhang ZC, Elicceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresh DA . 2001 Nature Med. 7: 222–227

  • Rosen K, Coll ML, Li A, Filmus J . 2001 J. Biol. Chem. 276: 37273–37279

  • Rosen K, Rak J, Jin J, Kerbel RS, Newman MJ, Filmus J . 1998 Curr. Biol. 8: 1331–1334

  • Rosen K, Rak J, Leung T, Dean NM, Kerbel RS, Filmus J . 2000 J. Cell Biol. 149: 447–455

  • Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT . 1994 Mol. Cell Biol. 14: 1680–1688

  • Schlessinger J . 2000 Cell 100: 293–296

  • Schmidt R, Streit M, Herzberg F, Schirner M, Schramm K, Kaufmann C, Henneken M, Schafer-Korting M, Thiel E, Kreuser E-D . 1998 Int. J. Cancer 76: 91–98

  • Staley CA, Parikh NU, Gallick GE . 1996 Cell Growth Differ. 8: 269–274

  • Strater J, Koretz K, Gunthert AR, Moller P . 1995 Gut 37: 819–825

  • Talamonti MS, Roh MS, Curley SA, Gallick GE . 1993 J. Clin. Invest. 91: 53–60

  • Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE . 1993 J. Surg. Res. 54: 293–298

  • Thomas SM, Brugge JS . 1997 Ann. Rev. Cell Dev. Biol. 13: 513–609

  • Wang NM, Yeh KT, Tsai CH, Chen SJ, Chang JG . 2000 Cancer Letts. 150: 201–204

  • Weiner TM, Liu ET, Craven RJ, Cance WG . 1993 Lancet 342: 1024–1025

  • Weng Z, Xin M, Pablo L, Grueneberg D, Hagel M, Muller T, Papkoff J . 2002 J. Biol. Chem. 277: 18677–18686

  • Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y . 1999 Mol. Cell 4: 1041–1049

  • Xiang L, Venegas AM, Chen A, Garret-Beal L, Boyce BF, Varmus HE, Schwartzberg PL . 2001 Genes Dev. 15: 241–253

  • Zhong M, Liu Z, Foster ZA . 2002 Oncogene 21: 1071–1078

Download references

Acknowledgements

We would like to thank Karen Ramirez and Kayo Nakano for their technical expertise in the cell cycle and immunoblotting analyses, respectively. This work was supported by CA53617, CA65527 and The Gillson Longenbaugh Foundation (GE Gallick), T32CA09599 (TC Windham) grants from the NIH, and by the American Cancer Society, Texas Branch (TC Windham).

Author information

Authors and Affiliations

  1. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, 77030, Texas, TX, USA

    T Christopher Windham, Nila U Parikh, Doris R Siwak, Justin M Summy, David J McConkey & Gary E Gallick

  2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, 77030, Texas, TX, USA

    T Christopher Windham

  3. Department of Cancer Research, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, 48105-2430, Michigan, MI, USA

    Alan J Kraker

Authors
  1. T Christopher Windham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nila U Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Doris R Siwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Justin M Summy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David J McConkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alan J Kraker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gary E Gallick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary E Gallick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Windham, T., Parikh, N., Siwak, D. et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21, 7797–7807 (2002). https://doi.org/10.1038/sj.onc.1205989

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205989

Keywords

This article is cited by

Search

Advanced search

Quick links